RESUMEN
A 7-year-old neutered female Domestic Short-haired cat was presented for evaluation of ulceration and severe vascularization of the left cornea. Ophthalmic examination revealed a large red irregular mass over the whole cornea in the left eye. A lamellar keratectomy was performed. Histopathology revealed a chronic lymphoplasmacytic, histocytic, neutrophilic ulcerative keratitis with fibrosis and vascularization. The tumor recurred within 3 months, and another lamellar keratectomy and sclerotomy were performed. The lesion was diagnosed histopathologically as a hemangiosarcoma with incomplete margins. The mass recurred locally 6 weeks later, and an enucleation was performed. Histopathology revealed infiltration of the limbus and connective tissue beyond the sclera. Seven weeks later, a fluctuant swelling was found in the left orbit. Computed tomography confirmed a soft tissue attenuating mass measuring 33 x 24 mm diameter in the orbit. There was no sign of metastasis. Clinical remission was achieved with combined chemotherapy with doxorubicin and radiation therapy. The patient remained in clinical remission 20 months post-chemotherapy.
Asunto(s)
Enfermedades de los Gatos/patología , Enfermedades de la Córnea/veterinaria , Neoplasias del Ojo/veterinaria , Hemangiosarcoma/veterinaria , Neoplasias Orbitales/veterinaria , Animales , Antineoplásicos/uso terapéutico , Enfermedades de los Gatos/cirugía , Enfermedades de los Gatos/terapia , Gatos , Terapia Combinada/veterinaria , Enfermedades de la Córnea/patología , Enfermedades de la Córnea/cirugía , Enfermedades de la Córnea/terapia , Doxorrubicina/uso terapéutico , Neoplasias del Ojo/patología , Neoplasias del Ojo/cirugía , Femenino , Hemangiosarcoma/patología , Hemangiosarcoma/cirugía , Hemangiosarcoma/terapia , Recurrencia Local de Neoplasia/veterinaria , Neoplasias Orbitales/secundario , Neoplasias Orbitales/cirugía , Neoplasias Orbitales/terapia , Radioterapia/veterinaria , Resultado del TratamientoRESUMEN
Bolus materials are commonly used for both human and veterinary radiation therapy (RT). Commercially available bolus materials often leave an air gap between the bolus and the skin which can lead to underdosing of the tumor. This prospective exploratory study evaluated the 6 MV X-ray and electron beam (6, 9, and 12 MeV) attenuating properties for two alternative bolus materials: McKesson lubricating jelly® (MLJ) and Aquasonic 100 Ultrasound gel® (AUG). The results comparing MLJ and water for 12 MeV and 9 MeV electron beams showed <3% difference, however, no other significant differences in radiation dose between water and MLJ nor AUG were seen. Findings demonstrated that both AUG and MLJ have radiation dose attenuating properties similar to water and supported use of these materials as alternative bolus materials for veterinary radiation therapy applications.
Asunto(s)
Lubricantes , Fantasmas de Imagen , Radioterapia/instrumentación , Ondas Ultrasónicas , Animales , Electrones , Geles , Radioterapia/veterinaria , Dosificación Radioterapéutica/veterinariaAsunto(s)
Enfermedades de los Perros , Oftalmopatías , Neoplasias del Seno Maxilar , Radioterapia , Animales , Enfermedades de los Perros/etiología , Enfermedades de los Perros/radioterapia , Perros , Oftalmopatías/etiología , Oftalmopatías/veterinaria , Neoplasias del Seno Maxilar/radioterapia , Neoplasias del Seno Maxilar/veterinaria , Radioterapia/efectos adversos , Radioterapia/veterinariaRESUMEN
As bone healing is altered after external radiation therapy, its evaluation is mandatory and lacks in clinical practice. The aim of the pilot study was to validate micro computed tomography (microCT) as a simple and reliable technique for assessing irradiated bone healing in the rabbit's mandible and compare with histologic findings. Nineteen rabbits (female New Zealand white) were used. The radiation protocol consisted of 5 sessions delivering 8.5 Gy each. MicroCT was performed at D0, D7, D14, D28 and D42 for the control group and D0, D28 and D42 for the irradiated group. A modified Perry's score was determined on histologic samples, and comparison between microCT and histological findings was performed. The main differences between irradiated and non-irradiated rabbits were observed at Day 28 and 42. There was a strong correlation between imaging and histologic findings. Radiation decreases bone quality and bone mineral density. As the correlation was strong between microCT and histologic findings, micro imaging could be considered as a simple and reliable technique to assess bone healing after radiation therapy and allows an easy comparison between samples, without invasive procedures. Great attention should be kept on the parameters and on the region of interest. The development of in-vivo microCT enlarges the perspectives of microCT use in experimental studies, avoiding invasive procedures, and preserving animal lives and well-being, and furthermore lead to clinical applications.
Asunto(s)
Enfermedades Óseas/veterinaria , Mandíbula/efectos de la radiación , Cicatrización de Heridas , Microtomografía por Rayos X , Animales , Densidad Ósea/efectos de la radiación , Femenino , Mandíbula/cirugía , Proyectos Piloto , Conejos , Radioterapia/veterinaria , Microtomografía por Rayos X/métodosRESUMEN
Thyroid carcinoma develops spontaneously in dogs, with only 25% to 50% of cases amenable to surgery at diagnosis. Local control for unresectable tumours can be provided with external beam radiotherapy. The aim of this retrospective study is to describe the safety and efficacy of stereotactic body radiation therapy (SBRT) for treatment of canine thyroid carcinoma. Twenty-three dogs met inclusion criteria; median tumour volume before SBRT was 129.9 cm3 (range, 2.7-452.8 cm3 ). Sixteen patients (70%) had unresectable tumours. Pulmonary metastasis was present or suspected in 10 patients (44%) before SBRT. Patients were prescribed 15 to 40 Gy to targeted tumour volume in one to five fractions. Twenty patients evaluated had overall response rate of 70% (complete response, n = 4; partial response, n = 10). Thirteen out of sixteen (81%) symptomatic patients had clinical improvement within a median time of 16 days (range, 2-79 days). Median progression free survival (MPFS) was 315 days. Median survival time (MST) was 362 days. Nine patients (39%) had grade 1 acute radiation toxicity. Three patients had grade 1 late radiation toxicity (two leukotrichia and one [4%] with intermittent cough). Responders had significantly longer MPFS (362 vs 90 days; HR 4.3; 95% CI 1.4-13.5; P = .013) and MST (455 vs 90 days; HR 2.9; 95% CI 1-8.4; P = .053). Presenting with metastasis was not a significant negative prognostic factor (MST 347 vs 348 days without metastasis; P = .352). SBRT is a safe and effective treatment modality for non-resectable canine thyroid carcinoma.
Asunto(s)
Carcinoma/veterinaria , Enfermedades de los Perros/radioterapia , Radioterapia/veterinaria , Neoplasias de la Tiroides/veterinaria , Animales , Carcinoma/mortalidad , Carcinoma/radioterapia , Colorado , Enfermedades de los Perros/mortalidad , Enfermedades de los Perros/patología , Perros , Femenino , Masculino , Metástasis de la Neoplasia , Dosis de Radiación , Radioterapia/efectos adversos , Radioterapia/métodos , Estudios Retrospectivos , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/radioterapia , Resultado del TratamientoRESUMEN
Treatment of epithelial sinonasal tumours in cats is not commonly reported. In the newer reports, palliative radiation protocols have been described more often than definitive-intent protocols. In this multi-institutional retrospective study, we included 27 cats treated with single-modality radiotherapy. Cats were irradiated using 10 daily fractions of 4.2 Gy. Three cats (11.1%) experienced a complete clinical response and 17 (63%) had a partial clinical response. Stable clinical disease was noted in three cats (11.1%). Four cats (14.8%) showed progression within 3 months following treatment. The median time to progression for all cases was 269 days (95 % confidence intervals [CI]: 225; 314). The proportion of cats free of progression at 1 and 2 years was 24% (95% CI: 22%; 26%) and 5% (95% CI: 5%; 6%), respectively. None of the prognostic factors evaluated were predictive of outcome (anaemia, tumour volume at the time of staging, modified Adams stage, intracranial involvement, facial deformity, epistaxis, inappetence or weight loss). Median overall survival (OS) for all deaths was 452 days (95% CI: 334; 571). The proportion of cats alive at 1 and 2 years was 57% (95% CI: 37%; 77%) and 27% (95% CI: 25%; 29%), respectively. Surprisingly, cats with epistaxis had a longer median OS of 828 days (95% CI: 356; 1301) compared to 296 days (95% CI: 85; 508) in cats without epistaxis, (P = .04, Breslow). Radiation therapy used as a single modality for the treatment of feline sinonasal carcinoma improved clinical signs and was well tolerated but progression within a year was common.
Asunto(s)
Carcinoma/veterinaria , Enfermedades de los Gatos/mortalidad , Enfermedades de los Gatos/radioterapia , Neoplasias Glandulares y Epiteliales/veterinaria , Neoplasias de los Senos Paranasales/veterinaria , Animales , Carcinoma/mortalidad , Carcinoma/patología , Carcinoma/radioterapia , Gatos , Femenino , Masculino , Neoplasias Glandulares y Epiteliales/mortalidad , Neoplasias Glandulares y Epiteliales/patología , Neoplasias Glandulares y Epiteliales/radioterapia , Neoplasias de los Senos Paranasales/mortalidad , Neoplasias de los Senos Paranasales/patología , Neoplasias de los Senos Paranasales/radioterapia , Portugal/epidemiología , Radioterapia/efectos adversos , Radioterapia/métodos , Radioterapia/veterinaria , Estudios Retrospectivos , SobrevidaRESUMEN
The purpose of this bi-institutional retrospective study was to determine whether survival for dogs with extremity osteosarcoma (OS) is improved through the use of stereotactic radiotherapy (SRT; a single fraction of 25 Gy, or 36 Gy total given in three consecutive daily fractions) plus chemotherapy, vs lower dose conventionally planned and delivered hypofractionated radiotherapy (CHRT; 14-20 Gy total in 1-2 consecutive daily fractions) plus chemotherapy. We also sought to determine whether baseline pain severity influences oncologic outcomes following radiotherapy for canine extremity OS. The medical records of 82 dogs undergoing radiotherapy for confirmed or presumed OS were reviewed. In dogs receiving combinations of both chemotherapy and radiotherapy, survival was significantly longer with SRT vs CHRT (median overall survival time: 350 vs 147 days; P = .031). In a univariate analysis, dogs with pulmonary metastases and high pain at the time of irradiation had short overall survival times; use of high radiation doses and chemotherapy were associated with improved survival. Separate multivariable models were built to assess the predictive nature of various factors that might influence event-free or overall survival in dogs treated with radiotherapy, with or without chemotherapy; for dogs treated with both chemotherapy and radiotherapy, overall survival times were significantly longer when baseline pain scores were 'low' (vs 'high'; hazard ratio: 0.258; P = .030), radiation doses were high (hazard ratio: 0.943; P = .034). Neither pain nor radiation dose were associated with survival in dogs treated with radiotherapy, without chemotherapy.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias Óseas/veterinaria , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/radioterapia , Osteosarcoma/veterinaria , Radioterapia/veterinaria , Animales , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/mortalidad , Neoplasias Óseas/radioterapia , Enfermedades de los Perros/mortalidad , Perros , Femenino , Fracturas Óseas/complicaciones , Fracturas Óseas/veterinaria , Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/secundario , Masculino , North Carolina/epidemiología , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/mortalidad , Osteosarcoma/radioterapia , Dolor/veterinaria , Dosis de Radiación , Radioterapia/métodos , Estudios Retrospectivos , SobrevidaRESUMEN
The use of conventional multi-fractionated radiotherapy for the treatment of glial tumours is well documented in the literature. Recently, stereotactic radiotherapy (SRT) has become more widely available allowing for hypo-fractionated protocols; however, its usefulness in the treatment of canine intracranial gliomas is largely undetermined. We conducted a retrospective analysis, including 21 dogs diagnosed with presumptive intracranial gliomas treated with one or more courses of three fractions of 8 to 10 Gy CyberKnife SRT. The objective of this study was to evaluate the efficacy, safety and prognostic factors associated with the use of SRT for the treatment of canine intracranial gliomas. Overall MST for all dogs was 636 days (d). Dogs treated with one course of the described SRT protocol had a MST of 258 days while those treated with >1 course had a MST of 865 days (P = .0077 log rank, 0.0139 Wilcoxon). Dogs treated with one course of SRT who received adjuvant chemotherapy had a MST of >658 days and lived significantly longer than those who did not receive chemotherapy (MST, 230 days) (P = .0414 log rank, 0.0453 Wilcoxon). The most common adverse event included presumptive transient demyelination in 3/21 dogs, which was treated successfully with corticosteroids in all patients. This study provides evidence that SRT is effective in prolonging survival in dogs with intracranial gliomas, and may provide similar results to conventional fractionated protocols, while decreasing the number of hospital visits and anaesthetic episodes. Additionally, it appears that patients can be safely treated with multiple rounds of SRT resulting in improved survival times.
Asunto(s)
Neoplasias Encefálicas/veterinaria , Enfermedades de los Perros/radioterapia , Glioma/veterinaria , Radioterapia/veterinaria , Animales , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/radioterapia , Enfermedades de los Perros/mortalidad , Perros , Glioma/mortalidad , Glioma/radioterapia , New York/epidemiología , Radioterapia/métodos , Estudios Retrospectivos , Sobrevida , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Recently, a multimodal approach to oral squamous cell carcinoma (SCC) in cats, combining medical treatment and accelerated radiation therapy, showed a substantial outcome improvement in a small pilot study. Herein we retrospectively review 51 cats with unresectable, histologically confirmed oral SCC and a complete initial staging work-up: cats in group A (n = 24) received medical anti-angiogenic treatment consisting of bleomycin, piroxicam and thalidomide, cats in group B (n = 27) received the anti-angiogenic treatment and concurrent accelerated hypofractionated radiation therapy with 48Gy delivered in 10 fractions. Overall median progression-free interval (PFI) was poor with 70 days (95% CI: 48;93). In the irradiated cats (group B), however, PFI was significantly longer with 179 days (95% CI: 58;301) days, vs 30 days (95% CI: 23;38) in medically only treated cats (P < .001). Overall median overall survival (OS) was 89 days (95% CI: 55;124), again significantly longer in the irradiated cats (group B) with 136 (95% CI: 40;233) vs 38 days (95% CI: 23;54) (P < .001). In 8 of the 27 (29.6%) cats in group B, however, severe toxicity (grade 3) occurred. Neither onset nor severity of toxicity could be associated with any of the tested variables, including anatomic site, tumour size, clinical stage and duration of neoadjuvant medical treatment. Given the potential severe acute effects and the impact on quality of life after chemo-radiotherapy, owners must be clearly informed about the risks of treatment. With the overall poor outcome and high occurrence of acute toxicity, we cannot recommend the use of this accelerated radiation protocol combined with anti-angiogenic therapy for oral SCC in cats.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Enfermedades de los Gatos/tratamiento farmacológico , Enfermedades de los Gatos/radioterapia , Neoplasias de la Boca/veterinaria , Hipofraccionamiento de la Dosis de Radiación , Carcinoma de Células Escamosas de Cabeza y Cuello/veterinaria , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Enfermedades de los Gatos/patología , Gatos , Femenino , Masculino , Neoplasias de la Boca/tratamiento farmacológico , Neoplasias de la Boca/patología , Neoplasias de la Boca/radioterapia , Radioterapia/efectos adversos , Radioterapia/métodos , Radioterapia/veterinaria , Estudios Retrospectivos , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Carcinoma de Células Escamosas de Cabeza y Cuello/radioterapia , Resultado del TratamientoRESUMEN
Critical weight loss, as defined by ≥5% decrease in body weight, has been associated with increased morbidity and mortality in human patients with cancers of the head and neck. Weight loss has anecdotally been reported to occur frequently in veterinary patients undergoing radiation therapy and is hypothesized to be more severe in patients with cancers of the head and neck, along with those hospitalized during radiation therapy. The primary objective of this retrospective study was to evaluate the occurrence of critical weight loss in canine cancer bearing patients undergoing either definitive or palliative radiation protocols and to determine if weight changes were associated with radiation toxicity, tumour location or patient hospitalization status. Data from 47 dogs who underwent definitive and 43 dogs who underwent palliative radiation protocols at the University of Tennessee were included for analysis. Dogs were categorized based on tumour location (head/neck or other), hospitalization status (boarded or non-boarded) and radiation toxicity score. Weight recorded at the start of treatment, midway through treatment and at the final treatment was used for analysis. No significant differences were found in regard to weight change over time, location or hospitalization status when evaluated for both protocols. Overall, 5/90 dogs (5.5%) lost 5% or more of their body weight during therapy, and 7/90 dogs (7.7%) gained 5% or more of their body weight. The results of the current study suggest that critical weight loss occurs in a small percentage of canine patients undergoing radiation therapy, contrary to what is often anecdotally reported.
Asunto(s)
Enfermedades de los Perros/radioterapia , Neoplasias/veterinaria , Radioterapia/veterinaria , Pérdida de Peso , Animales , Perros , Femenino , Masculino , Neoplasias/radioterapia , Radioterapia/efectos adversos , Estudios Retrospectivos , Factores de RiesgoRESUMEN
OBJECTIVES: To describe alfentanil-propofol admixture for induction of anaesthesia for canine radiotherapy and compare it to alfentanil-atropine followed by propofol induction in terms of heart rate (HR), mean arterial pressure (MAP), recovery duration and quality. STUDY DESIGN: Prospective, masked, randomized clinical crossover trial. ANIMALS: A group of 40 client-owned dogs anaesthetized from October 2017 to June 2018. METHODS: Dogs were randomly assigned to be administered one of two protocols. For both protocols, IV preanaesthetic medication was given 30 seconds before rapid IV administration of a set volume of induction agent, with further induction agent administered as needed to permit intubation. For protocol ADMIX, the preanaesthetic medication was 0.04 mL kg-1 0.9% sodium chloride and the induction agent was 0.2 mL kg-1 propofol-alfentanil admixture. For protocol ATRO, the preanaesthetic medication was 10 µg kg-1 alfentanil with 12 µg kg-1 atropine (0.04 mL kg-1 total volume) and the induction agent was 0.2 mL kg-1 propofol. Anaesthesia was maintained with sevoflurane. Cardiorespiratory variables, agitation, hypotension, or inadequate depth of anaesthesia requiring supplemental boluses of propofol or increased vaporizer settings were recorded. Time to extubation, sternal recumbency and walking was noted. Videos were recorded for recovery quality scoring. Owner questionnaires gave feedback about recoveries at home. The other protocol was administered for the next radiotherapy session. RESULTS: The only significantly different variable between protocols was mean HR during anaesthesia, which was lower in ADMIX (p < 0.001). Hypotension was recorded in seven (17.5%) dogs in ATRO and three (7.5%) in ADMIX, with an association (p < 0.005) between ATRO and hypotension. Owners reported animals recovered 'normal' behaviour and appetite by the next morning. CONCLUSIONS AND CLINICAL RELEVANCE: Both protocols were acceptable for dogs undergoing radiotherapy, with minimal differences in anaesthetic quality, recovery duration and quality. Although MAP did not differ overall, the incidence of hypotension was higher in ATRO.
Asunto(s)
Alfentanilo/farmacología , Anestesia/veterinaria , Atropina/farmacología , Enfermedades de los Perros/radioterapia , Propofol/farmacología , Radioterapia/veterinaria , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/farmacología , Alfentanilo/administración & dosificación , Anestésicos Intravenosos/administración & dosificación , Anestésicos Intravenosos/farmacología , Animales , Atropina/administración & dosificación , Estudios Cruzados , Perros , Femenino , Masculino , Medicación Preanestésica/veterinaria , Propofol/administración & dosificaciónRESUMEN
Histiocytic sarcoma (HS) and hemangiosarcoma (HSA) are uncommon and aggressive neoplasms that develop much more frequently in dogs than in cats. Breed-specific predispositions have been identified for both cancers. The development of novel diagnostics is underway and may aid in earlier diagnosis. Therapeutic approaches to HS and HSA depend on the stage of disease and may include surgery, radiation therapy, and chemotherapy. Such interventions improve outcome; however, aside from a small number of clinical circumstances, both diseases are considered largely incurable. Continued efforts toward the identification of driver mutations and subsequent druggable targets may lead to improvements in long-term prognosis.
Asunto(s)
Enfermedades de los Gatos/patología , Enfermedades de los Gatos/terapia , Enfermedades de los Perros/patología , Enfermedades de los Perros/terapia , Hemangiosarcoma/veterinaria , Sarcoma Histiocítico/veterinaria , Animales , Enfermedades de los Gatos/epidemiología , Gatos , Quimioradioterapia Adyuvante/métodos , Quimioradioterapia Adyuvante/veterinaria , Enfermedades de los Perros/epidemiología , Perros , Hemangiosarcoma/epidemiología , Hemangiosarcoma/patología , Hemangiosarcoma/terapia , Sarcoma Histiocítico/patología , Sarcoma Histiocítico/terapia , Cuidados Paliativos , Pronóstico , Radioterapia/métodos , Radioterapia/veterinaria , SobrevidaRESUMEN
Stereotactic radiotherapy (SRT) involves the precise delivery of highly conformal, dose-intense radiation to well-demarcated tumors. Special equipment and expertise are needed, and a unique biological mechanism distinguishes SRT from other forms of external beam radiotherapy. Families find the convenient schedules and minimal acute toxicity of SRT appealing. Common indications in veterinary oncology include nasal, brain, and bone tumors. Many other solid tumors can also be treated, including spinal, oral, lung, heart-base, liver, adrenal, and prostatic malignancies. Accessibility of SRT is improving, and new data are constantly emerging to define parameters for appropriate case selection, radiation dose prescription, and long-term follow-up."
Asunto(s)
Enfermedades de los Gatos/radioterapia , Enfermedades de los Perros/radioterapia , Neoplasias/veterinaria , Animales , Gatos , Perros , Oncología Médica , Neoplasias/radioterapia , Oncología por Radiación/métodos , Radiocirugia/métodos , Radiocirugia/veterinaria , Radioterapia/métodos , Radioterapia/veterinaria , Dosificación Radioterapéutica/veterinaria , Medicina VeterinariaRESUMEN
Lymphoma is a common disease in companion animals. Although conventional chemotherapy has the potential to induce remission and prolong life, relapse is common, and novel treatments are needed to improve outcome. This review discusses recent modifications/adjustments to conventional standard of care therapy for canine and feline lymphoma, as well as cutting-edge immunotherapy and small-molecule-based approaches that are in varying stages of regulatory approval.
Asunto(s)
Enfermedades de los Gatos/terapia , Enfermedades de los Perros/terapia , Linfoma/veterinaria , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Vacunas contra el Cáncer/uso terapéutico , Gatos , Perros , Inmunoterapia/métodos , Inmunoterapia/veterinaria , Linfoma/terapia , Recurrencia Local de Neoplasia , Pronóstico , Radioterapia/métodos , Radioterapia/veterinariaRESUMEN
INTRODUCTION: Acromegaly due to a pituitary tumor has so far only been described in 3 dogs. The present case report describes a 7-year-old male-castrated Labrador Retriever which was referred because of difficult-to-control diabetes. Physical examination revealed markedly enlarged head, tongue and paws, widened interdental spaces and thickening of the skin in the head and neck area. IGF-1 and GH were increased and the latter continued to be abnormal after somatostatin application. Computed tomography demonstrated a space-occupying lesion in the pituitary gland and the diagnosis of acromegaly due to a GH-producing tumor of the pituitary was made. The dog underwent radiation therapy with a 6MV linear accelerator (3×8Gy) and improved substantially. Two and a half years after radiation therapy the dog developed lethargy and anorexia and was euthanized. Necropsy was not permitted. This case report represents the description of a dog suffering from pituitary-dependent acromegaly which was successfully treated and had a long-term survival.
INTRODUCTION: L'acromégalie due à une tumeur hypophysaire n'a jusqu'à présent été décrite que chez 3 chiens. Le présent rapport de cas décrit un Labrador Retriever de 7 ans mâle castré, qui a été référé en raison d'un diabète difficile à contrôler. L'examen physique a révélé une tête, une langue et des pattes de taille nettement augmentée, des espaces interdentaires élargis et un épaississement de la peau dans la région de la tête et du cou. L'IGF-1 et la GH étaient augmentées et la seconde restait anormale après l'application de somatostatine. La tomodensitométrie a mis en évidence une masse dans la région de l'hypophyse et le diagnostic d'acromégalie due à une tumeur de l'hypophyse productrice de GH a été posé. Le chien a subi une radiothérapie avec un accélérateur linéaire de 6MV (3×8Gy) et son état s'est considérablement amélioré. Deux ans et demi après la radiothérapie, le chien développa une léthargie et une anorexie et fut euthanasié. L'autopsie n'a pas été autorisée. Ce rapport de cas représente la description d'un chien souffrant d'acromégalie dépendant de l'hypophyse, traité avec succès et ayant une survie à long terme.
Asunto(s)
Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/terapia , Adenoma Hipofisario Secretor de Hormona del Crecimiento/veterinaria , Animales , Enfermedades de los Perros/sangre , Perros , Hormona del Crecimiento/sangre , Adenoma Hipofisario Secretor de Hormona del Crecimiento/sangre , Adenoma Hipofisario Secretor de Hormona del Crecimiento/diagnóstico , Adenoma Hipofisario Secretor de Hormona del Crecimiento/terapia , Hormonas/uso terapéutico , Factor I del Crecimiento Similar a la Insulina/análisis , Masculino , Radioterapia/veterinaria , Somatostatina/uso terapéutico , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Although lung lobectomy is the most common treatment option for dogs with solitary lung tumors, surgery often cannot be performed at the time of diagnosis. In this retrospective, case series study, we described the effects of hypofractionated radiotherapy for tumor mass reduction in nine dogs with solitary lung adenocarcinoma that were later considered for surgical resection, and we assessed the tolerability of the radiation protocol. Tumors were deemed unresectable by the attending veterinarian. The dose prescription was 7.0-12.0 Gy/fraction in four to seven fractions, administered weekly for a total dose of 40-50 Gy. Treatment planning prioritized normal tissue dose constraints. The median interval between the last radiotherapy session and maximum tumor size reduction was 56 (range: 26-196) days, with six and three dogs exhibiting a partial response and stable disease, respectively. Although acute and late radiation-induced toxicity to the skin and/or lungs developed in all nine dogs, it was self-limiting or improved with short-term anti-inflammatory treatment. Tumor progression after initial size reduction was confirmed in three dogs at 62, 126, and 175 days, respectively, after the last radiotherapy session. Seven of the nine dogs underwent lobectomy a median of 68 days after radiotherapy when tumors were in partial response or stable disease or at the time of progression, and five received systemic chemotherapy concurrent with or after radiotherapy. These findings suggest that hypofractionated radiotherapy for canine solitary lung adenocarcinoma is useful when the tumor is large or when surgery cannot be performed immediately after diagnosis.
Asunto(s)
Adenocarcinoma del Pulmón/veterinaria , Enfermedades de los Perros/radioterapia , Neoplasias Pulmonares/veterinaria , Hipofraccionamiento de la Dosis de Radiación , Radioterapia/veterinaria , Adenocarcinoma del Pulmón/radioterapia , Animales , Perros , Femenino , Neoplasias Pulmonares/radioterapia , Masculino , Traumatismos por Radiación/tratamiento farmacológico , Traumatismos por Radiación/veterinaria , Radioterapia/métodos , Estudios RetrospectivosRESUMEN
An 8 yr old female spayed poodle/terrier mixed-breed dog was referred for evaluation of a recurrent and metastatic ovarian dysgerminoma. A total dose of 20Gy was administered to both the mediastinal metastatic lesion and retroperitoneal recurrent dysgerminoma in five daily fractions of 4Gy. Acute side effects were mild and self-limiting. This was followed by several courses of chemotherapy using a variety of agents. Despite extensive disease, this patient was still alive at the time of publication, 524 days after presentation and 501 days following completion of radiation. This case report demonstrates tolerability and efficacy of palliative radiation and chemotherapy for this rare tumor type.
Asunto(s)
Antineoplásicos/uso terapéutico , Enfermedades de los Perros/terapia , Disgerminoma/veterinaria , Enfermedades del Ovario/veterinaria , Radioterapia/veterinaria , Animales , Perros , Disgerminoma/patología , Disgerminoma/terapia , Femenino , Enfermedades del Ovario/patología , Enfermedades del Ovario/terapiaRESUMEN
Veterinary clients may have trepidation about treating their pet with radiotherapy because of concerns about radiation side effects or repeated anaesthetics. The purpose of this study is to assess whether owners' attitudes towards veterinary radiotherapy, including concerns over side effects, change during the course of treatment, and whether radiotherapy was perceived to affect pets' quality of life (QOL). A prospective cohort study of clients from 2012 to 2015 was performed. Pets received palliative or definitive radiotherapy for various tumours. Clients completed questionnaires before, during and after radiotherapy. Questions assessed owner preconceptions before treatment, including side effect expectations, actual side effects experienced and overall satisfaction with the process. In addition, at each time point, the owners assessed their pet's QOL using a simple numerical scale. Forty-nine patients were included. After completing treatment, owners were significantly less concerned about potential side effects of radiotherapy (P < 0.001), side effects associated with repeat anaesthetics (P < 0.001), and about radiotherapy in general (P < 0.001). QOL did not show a significant change at any point during or after treatment. Following treatment, 94% reported that the experience was better than expected and 100% supported the use of radiotherapy in pets. This is the first prospective study evaluating client attitudes and satisfaction before and after radiotherapy treatment in pets. The results indicate that radiotherapy is well tolerated, and the anxiety associated with radiotherapy is significantly alleviated after experiencing the process. These results will help veterinarians allay client concerns, and will hopefully lead to an increase in clients pursuing radiotherapy in pets.
Asunto(s)
Enfermedades de los Gatos/radioterapia , Enfermedades de los Perros/radioterapia , Neoplasias/veterinaria , Percepción , Radioterapia/veterinaria , Animales , Gatos , Recolección de Datos , Perros , Humanos , Neoplasias/radioterapia , Propiedad , Encuestas y CuestionariosRESUMEN
Despite a major paradigm shift in radiotherapy planning and delivery over the past three decades with continuing refinements, radiation-induced lung damage (RILD) remains a major dose limiting toxicity in patients receiving thoracic irradiations. Our current understanding of the biological processes involved in RILD which includes DNA damage, inflammation, senescence and fibrosis, is based on clinical observations and experimental studies in mouse models using conventional radiation exposures. Whilst these studies have provided vital information on the pulmonary radiation response, the current implementation of small animal irradiators is enabling refinements in the precision and accuracy of dose delivery to mice which can be applied to studies of RILD. This review presents the current landscape of preclinical studies in RILD using small animal irradiators and highlights the challenges and opportunities for the further development of this emerging technology in the study of normal tissue damage in the lung.
Asunto(s)
Pulmón/efectos de la radiación , Neumonitis por Radiación/veterinaria , Radioterapia/veterinaria , Animales , Investigación Biomédica , Modelos Animales de Enfermedad , Pulmón/patología , Ratones , Neumonitis por Radiación/fisiopatología , Dosificación RadioterapéuticaRESUMEN
OBJECTIVES: The aim of this retrospective, bi-institutional study was to evaluate the progression-free interval in a cohort of cats with postoperative microscopic injection-site sarcoma (ISS) treated with two different radiotherapy protocols. METHODS: Included in the study were cats with ISSs undergoing macroscopic surgical removal and subsequent electron beam radiotherapy treatment with either a finely fractionated protocol (48 or 52.8 Gy over 4 weeks delivered in 12 or 16 fractions) or a coarsely fractionated protocol (36 Gy over 3 weeks administered in six fractions). Medical records were reviewed and follow-up information was collected. The Kaplan-Meier method and log-rank test were used to compare the progression-free interval (PFI) between the two protocols and to test the influence of many clinical variables. RESULTS: Fifty-nine cats were included; 38 underwent a finely fractionated protocol and 21 a coarsely fractionated protocol. PFI was not significantly different between the two groups. Overall PFI was 2000 days (2000 vs 540 days; P = 0.449). When only first-occurrence cases were included, median PFI was significantly longer in the finely fractionated group compared with the coarsely fractionated group (1430 vs 540 days; P = 0.007). In cats that underwent multiple surgeries PFI was not different between protocols (233 vs 395 days; P = 0.353). CONCLUSIONS AND RELEVANCE: Cats with first-occurrence ISSs appear to benefit from postoperative finely fractionated radiotherapy. The same benefit was not evident in cats that underwent multiple surgeries and we think a coarsely fractionated protocol would be indicated in these cases.